Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli
Cunningham, Scott A. , Cole, Nicolynn C., Kohner, Peggy C., Menon, Sanjay , Krause, Kevin M. , Harris, Kelly , De, Partha Pratim, Koh, Tse Hsien , Patel, Robin , Vasoo, Shawn , Patel, Robin , Cunningham, Scott A

Antimicrobial Agents and Chemotherapy | September 22, 2015 | Volume: 59 | Issue: 12 | Pages: 7842-7846

10.1128/aac.02019-15 | PMID 26392487 Get It

ABSTRACT Among 177 carbapenemase-producing Gram-negative bacilli (108 KPC, 32 NDM, 11 IMP, 8 OXA-48, 4 OXA-181, 2 OXA-232, 5 IMI, 4 VIM, and 3 SME producers), aztreonam-avibactam was active against all isolates except two NDM producers with elevated MICs of 8/4 and 16/4 mg/liter; ceftazidime-avibactam was active against all KPC-, IMI-, SME-, and most OXA-48 group-producing isolates (93%) but not metallo-β-lactamase producers. Among older and contemporary antimicrobials, the most active were colistin, tigecycline, and fosfomycin, with overall susceptibilities of 88%, 79%, and 78%, respectively.
Disease relevance of phosphorylated ubiquitin (p-S65-Ub)
Fiesel, Fabienne C. , Springer, Wolfdieter , Fiesel, Fabienne C , Springer, Wolfdieter

Autophagy | September 21, 2015 | Volume: 11 | Issue: 11 | Pages: 2125-2126

10.1080/15548627.2015.1091912 | PMID 26389970 Get It

The cytological diagnosis of a ‘benign thyroid lesion’: is it a real safe diagnosis for the patient?
Rossi, Esther Diana , Bizzarro, Tommaso , Fadda, Guido , Pontecorvi, Alfredo , Bernet, Victor , Nassar, Aziza , Nassar, Aziza , Rossi, Esther Diana

Cytopathology | September 21, 2015 | Volume: 27 | Issue: 3 | Pages: 168-175

10.1111/cyt.12267 | PMID 26388423 Get It

ObjectiveIn fine needle aspiration cytology (FNAC), the category of benign thyroid lesions (BTL), which constitutes 65–70% of all thyroid FNAC, and can be correctly diagnosed by morphology alone, is an important entity. A diagnosis of BTL denotes a lesion managed with follow‐up unless found in conjunction with compressive symptoms. Although this diagnosis can be quite simple, there are cases in which the scant cellular or colloid component may pose diagnostic issues. Herein, we describe the experiences of evaluating BTL at two large academic institutions. We evaluated the clinical importance of a correct diagnosis of BTL to define the exact inherent risk of a false‐negative result (FNR).MethodsFrom January 2008 through to June 2013, 506 (3.6%) out of 15 850 patients with BTL underwent surgery. All nodules were sampled under sonographic guidance (US) and processed either with liquid‐based cytology (LBC), Diff‐Quik® smears or alcohol‐Papanicolaou staining methods.ResultsThe histological follow‐up of 506 BTL series included 493 benign and 13 malignant lesions. The latter group included four follicular carcinomas (FC), two classic variants of papillary thyroid carcinoma (PTC), one macrofollicular PTC and six follicular variants of PTC (FVPC). The malignancy rate for the BTL category was 2.5%.ConclusionsWhen diagnosed by expert cytopathologists, BTL represents a robust diagnosis and might reduce the number of FNR. Additional diagnostic experience and a large case series could enable cytopathologists to recognise all the morphological entities of BTL. An important additional aid is the extensive sampling of the lesions to reduce issues related to a low cellularity.
Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders
Parthasarathy, Gopanandan , Camilleri, Michael , Szarka, Lawrence A., Low, P. A., Zinsmeister, A. R., Bharucha, Adil E. , Ravi, Karthik , Andrews, Christopher N.

Neurogastroenterology & Motility | September 21, 2015 | Volume: 27 | Issue: 12 | Pages: 1736-1746

10.1111/nmo.12669 | PMID 26387781 Get It

Abstract Background Acetylcholinesterase inhibitors ( ACI s), e.g., neostigmine, are known to increase upper and lower gastrointestinal ( GI ) motility and are used to treat acute colonic pseudoobstruction. However, their effects on gastroduodenal motility in humans are poorly understood. Our hypotheses were that, in patients with suspected GI motility disorders, neostigmine increases gastric and small intestinal motor activity, and these effects are greater in patients with cardiovagal neuropathy, reflecting denervation sensitivity. Methods In this open label study, the effects of neostigmine (1 mg intravenously) on gastroduodenal motor activity recorded with manometry were assessed in 28 patients with a suspected GI motility disorder. Cardiovagal function was assessed with the heart rate response to deep breathing and GI transit by scintigraphy. Key Results The final diagnoses were gastroparesis (6 patients), gastroparesis with intestinal neuropathy (3 patients), intestinal neuropathy or pseudoobstruction (5 patients), functional dyspepsia (6 patients), chronic abdominal pain (3 patients), mechanical small intestinal obstruction (3 patients), and pelvic floor dysfunction (2 patients). Neostigmine increased both antral and intestinal phasic pressure activity ( p < 0.001). Neostigmine increased antral and intestinal pressure activity in 81% and 50% of patients with reduced postprandial antral and intestinal contractile responses to meal, respectively. The antroduodenal pressure response to neostigmine was not higher in patients with cardiovagal dysfunction. Conclusions & Inferences Neostigmine increased antral and intestinal motor activity in patients with hypomotility, including intestinal dysmotility. These responses to neostigmine were not greater in patients with cardiovagal dysfunction. The use of longer‐acting ACI s for treating antroduodenal dysmotility warrant further study.
Perspectives on a Multidisciplinary Team Approach to Implementation of Planned Emergent Use Research
Africano, Carlos J. Racedo, Moraes, Alice Gallo de , Racedo Africano, Carlos J, Gallo de Moraes, Alice, Smischney, Nathan J. , Gallo de Moraes, Alice

Medical Science Monitor | September 20, 2015 | Volume: 21 | Issue: No issue available | Pages: 2794-2800

10.12659/msm.894327 | PMID 26386913 Get It

Acquiring New Technical Skills and Aptitude for Mental Rotation
Kopp, Sandra L. , Rathmell, James P. , Kopp, Sandra

Anesthesiology | September 19, 2015 | Volume: 123 | Issue: 5 | Pages: 993-994

10.1097/aln.0000000000000871 | PMID 26389553 Get It

Response to Fibrosis progression in patients treated for hepatitis C recurrence
Dhanasekaran, Renumathy , Sánchez, William , Charlton, Michael , Dhanasekaran, Renumathy , Sanchez, William

Liver International | September 19, 2015 | Volume: 35 | Issue: 12 | Pages: 2625-2625

10.1111/liv.12969 | PMID 26386267 Get It

MalignantTFE3-rearranged perivascular epithelioid cell neoplasm (PEComa) presenting as a subcutaneous mass
Shon, Wonwoo , Kim, J, Sukov, William R. , Reith, John D.

British Journal of Dermatology | September 19, 2015 | Volume: 174 | Issue: 3 | Pages: 617-620

10.1111/bjd.14173 | PMID 26385848 Get It

SummaryPerivascular epithelioid cell neoplasms (PEComas) are a group of mesenchymal tumours with concurrent melanocytic and myogenic differentiation. Although many cases are sporadic, PEComas can be associated with tuberous sclerosis. A distinct subset of deep-seated PEComas has been shown to carry TFE3 fusions. To our knowledge, this is the first reported case of primary subcutaneous malignant PEComa with molecular confirmation of TFE3 gene rearrangement.
The benefits of the patient experience: one dermatology resident's perspective
Laniosz, Valerie

British Journal of Dermatology | September 19, 2015 | Volume: 174 | Issue: 3 | Pages: 681-681

10.1111/bjd.14171 | PMID 26385587 Get It